FDA to weigh easing limits on unproven peptides promoted by RFK Jr. Mitigating Risks of Compounded Drugs Through Surveillance FDA The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA mulls compounding for peptides previously flagged over safety risks BioSpace Regeneration or Risk? A Narrative Review of BPC 157 for Musculoskeletal Healing Current Reviews in Musculoskeletal Medicine Springer Nature Link Have patients been harmed by unsafe drug compounding? Partnership for Safe Medicines